罗沙司他治疗腹膜透析肾性贫血的临床观察

Clinical Observation of Roxadustat in the Treatment of Peritoneal Dialysis Renal Anemia

目的观察对腹膜透析肾性贫血患者实施罗沙司他治疗的临床效果。方法从2020年3月—2021年3月择取70例腹膜透析肾性贫血患者,将其按照数字随机表法予以分组,每组35例,对照组实施促红细胞生成素治疗,研究组实施罗沙司他治疗,对照分析两组临床效果。结果从血液指标分析,治疗后研究组血细胞比容、血红蛋白高于对照组(P<0.05),两组红细胞计数对比差异无统计学意义(P>0.05);从脂代谢指标分析,治疗后研究组总胆固醇、低密度脂蛋白胆固醇水平低于对照组,高密度脂蛋白胆固醇水平高于对照组(P<0.05);从铁代谢指标分析,治疗后研究组铁蛋白、血清铁、铁转蛋白饱和度水平高于对照组(P<0.05);从炎症指标分析,治疗后研究组C反应蛋白、超敏C反应蛋白、白介素-6水平均低于对照组(P<0.05);从不良反应发生情况分析,研究组食欲减退、轻度腹胀、头晕等不良反应总发生率低于对照组(P<0.05)。结论对腹膜透析肾性贫血患者来说,实施罗沙司他治疗可以改善贫血,对炎症有抑制作用,可以改善脂代谢和铁代谢状况,而且安全性良好,临床价值显著。

Objective To observe the clinical effect of roxadustat on peritoneal dialysis patients with renal anemia.Methods From March 2020 to March 2021,70 patients with renal anemia on peritoneal dialysis were selected and divided into 35 patients in each group according to the numerical random table method.The control group was treated with erythropoietin and the study group was treated with roxadustat.The clinical effects of the two groups were analyzed.Results After treatment,hematocrit and hemoglobin in the study group were higher than those in the control group(P<0.05),and there was no statistical difference in red blood cell count between the two groups(P>0.05).After treatment,the levels of total cholesterol and low density lipoprotein cholesterol in the study group were lower than those in the control group,while the levels of high density lipoprotein cholesterol were higher than that in the control group(P<0.05).After treatment,the levels of ferritin,serum iron and ferritransferrin saturation in the study group were higher than those in the control group(P<0.05).After treatment,the levels of C-reactive protein,hypersensitive C-reactive protein and interleukin-6 in the study group were lower than those in the control group(P<0.05).From the analysis of the occurrence of adverse reactions,the total incidence of anorexia,mild abdominal distension,dizziness and other adverse reactions in the study group were lower than that in the control group(P<0.05).Conclusion For patients with renal anemia on peritoneal dialysis,roxadustat treatment can improve anemia,inhibit inflammation,and improve lipid metabolism and iron metabolism,with good safety and significant clinical value.